Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
High-dose ifosfamide, carboplatin and etoposide with autologous peripheralblood progenitor cell transplantation for small-cell lung cancer
Autore:
Bessho, A; Ueoka, H; Kiura, K; Tabata, M; Sunami, K; Katayama, Y; Yamane, H; Hiraki, A; Harada, M;
Indirizzi:
Okayama Univ, Sch Med, Dept Internal Med 2, Okayama 7008558, Japan OkayamaUniv Okayama Japan 7008558 nternal Med 2, Okayama 7008558, Japan
Titolo Testata:
ANTICANCER RESEARCH
fascicolo: 1B, volume: 19, anno: 1999,
pagine: 693 - 698
SICI:
0250-7005(199901/02)19:1B<693:HICAEW>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
STEM-CELL; BONE-MARROW; SOLID TUMORS; PHASE-I; CHEMOTHERAPY; MOBILIZATION; THERAPY; TOXICITY; RESCUE; CRYOPRESERVATION;
Keywords:
high-dose chemotherapy; autologous peripheral blood progenitor cell transplantation; small-cell lung cancer; ifosfamide; carboplatin; etoposide;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
35
Recensione:
Indirizzi per estratti:
Indirizzo: Bessho, A Okayama558,v, Sch Med, Dept Internal Med 2, 2-5-1 Shikata Cho, Okayama 7008 Okayama Univ 2-5-1 Shikata Cho Okayama Japan 7008558 ayama 7008
Citazione:
A. Bessho et al., "High-dose ifosfamide, carboplatin and etoposide with autologous peripheralblood progenitor cell transplantation for small-cell lung cancer", ANTICANC R, 19(1B), 1999, pp. 693-698

Abstract

Background: We investigated the feasibility and efficacy of high-dose chemotherapy consisting of ifosfamide, carboplatin and etoposide (HD-ICE) facilitated by autologous peripheral blood progenitor cell transplantation (ABPCT) for the treatment of small-cell lung cancer (SCLC). Patients and Methods: Eleven patients aged 44 to 63 years old (5 with extensive disease [ED] and 6 with limited disease [LD]) were entered into this study. Induction chemotherapy consisted for 3 to 4 cycles of cisplating and irinotecan for Ed-SCLC, and cisplatin and etoposide for LD-SCLC. Patients with LD-SCLC receivedconcurrent chest radiotherapy along with the first cycle of induction chemotherapy. After induction therapy, peripheral blood progenitor cells (PBPC)were collected following G-CSF administration during a recovery phase fromhigh-dose etoposide (1,500 mg/m(2)). Eight patients (4 with ED and 4 with LD) with adequate organ function were treated with HD-ICE (15g/m(2) ifosfamide, 1,200 mg/m(2) carboplatin and 1,500 mg/m(2) etoposide) followed by ABPCT. Results: Hematologic recovery was rapid and non-hematological toxicities were acceptable without treatment-related mortality. In ED-SCLC, all of the 4 patients achieved complete response (CR) or near CR but developed a relapse of the disease. In LD-SCLC, 2 of 4 patients with LD-SCLC are alive incontinuous CR for 18 and 21 months after the beginning of induction therapy. Conclusions: Despite a limited number of patients and short follow-up time, these preliminary results indicate that marrow-ablative therapy (HD-ICE) supported by ABPCT is feasible in the treatment of elderly patients with LD- and ED-SCLC.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 18:32:52